

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>El-Hibri Fuad</u>  (Last) (First) (Middle) 2273 RESEARCH BLVD, SUITE 400  (Street) ROCKVILLE MD 20850  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [ EBS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>CEO &amp; Chairman</b>
	3. Date of Earliest Transaction (Month/Day/Year) 08/28/2008	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/28/2008		S <sup>(1)</sup>		8,000	D	\$14	7,843,735 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		200	D	\$14.005	7,843,535 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		300	D	\$14.01	7,843,235 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		500	D	\$14.02	7,842,735 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		800	D	\$14.03	7,841,935 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		100	D	\$14.04	7,841,835 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		200	D	\$14.05	7,841,635 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		3,700	D	\$14.06	7,837,935 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		1,700	D	\$14.07	7,836,235 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		400	D	\$14.08	7,835,835 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		100	D	\$14.085	7,835,735 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		350	D	\$14.09	7,835,385 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		600	D	\$14.1	7,834,785 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		300	D	\$14.11	7,834,485 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		600	D	\$14.12	7,833,885 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		700	D	\$14.13	7,833,185 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		200	D	\$14.14	7,832,985 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		100	D	\$14.15	7,832,885 <sup>(1)</sup>	I	By Interac, L.L.C.

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	08/28/2008		S <sup>(1)</sup>		50		D	\$14.16	7,832,835 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		800		D	\$14.17	7,832,035 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		400		D	\$14.18	7,831,635 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		1,000		D	\$14.19	7,830,635 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		500		D	\$14.2	7,830,135 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		200		D	\$14.21	7,829,935 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		650		D	\$14.22	7,829,285 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock	08/28/2008		S <sup>(1)</sup>		100		D	\$14.23	7,829,185 <sup>(1)</sup>	I	By Interac, L.L.C.
Common Stock									246,992	D	
Common Stock									3,665,043 <sup>(2)</sup>	I	By BioPharm, L.L.C.
Common Stock									1,599,155 <sup>(3)</sup>	I	By Biovac, L.L.C.
Common Stock									719,275 <sup>(4)</sup>	I	By Intervac Management, L.L.C.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Intervac, L.L.C. on June 13, 2008. Intervac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following each of the reported sales. Both before and after the reported sales, Mr. El-Hibri held, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein.
- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 3,665,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

/s/ Joseph J. Kaufman,  
attorney-in-fact

09/02/2008

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.